Result of General Meeting & Total Voting Rights

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA, THE REPUBLIC OF IRELAND, NEW ZEALAND OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY PERSON TO SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY SECURITIES IN QUANTUM PHARMA PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF, OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF QUANTUM PHARMA PLC.

Quantum Pharma Plc

('Quantum' or the 'Company')

Result of General Meeting & Total Voting Rights

Quantum Pharma Plc (AIM: QP.) the service-led niche pharmaceutical developer, manufacturer and supplier to the health and care sectors, announced on 20 October 2016 that the Company had raised a total of £15 million (before expenses) by means of an accelerated bookbuild with new and existing investors, of 44,117,647 Placing Shares at a price of 34 pence per share. The Placing was subject, inter alia, to the approval by Shareholders of certain resolutions set out in the Notice of General Meeting issued on 21 October 2016.

The Company is pleased to announce that at the General Meeting, which was held in Newcastle upon Tyne earlier today, all resolutions were duly passed.

An application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and it is expected that Admission will occur and that dealings will commence at 8.00 a.m. on 11 November 2016.

Upon Admission, the Company's issued share capital will comprise 169,117,640 Ordinary Shares with one voting right per share. The Company does not hold any Ordinary Shares in treasury. Therefore, this figure of 169,117,640 Ordinary Shares may be used by Shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Unless otherwise stated, definitions used in this announcement carry the same meaning as those set out in the circular to Shareholders dated 21 October 2016.

- Ends -

For further information:

Notes to Editors

Quantum Pharma Plc is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesaler, hospital, homecare and care home markets. Quantum Pharma operates through three divisions: Specials, Niche Pharmaceuticals and Medication Adherence, offering a portfolio of innovative and complementary products and services.

Specials comprises three business units (Quantum Pharmaceutical, UL Medicines and Quantum Aseptics Services). This division manufactures, procures and supplies bespoke specials; batch made specials; aseptically prepared sterile intravenous medicines; imported medicines and special obtain products in response to a request from a prescriber for a bespoke medicine or special product to optimise patient treatment. The division offers an unrivalled and constantly expanding range of products. It has a customer-focused, service-driven business model, which provides shorter lead times than any of its competitors.

Niche Pharmaceuticals comprises three business units (Colonis, Lamda and PERN Consumer Products). This division is a product development and commercialisation business focusing on taking niche drugs through the regulatory pathway to achieve regulated status (licensed product or medical device). The division uses the excellent visibility of trends in the UK pharmacy and hospital markets gained through our Specials and Medication Adherence divisions, to allow early identification of the market opportunity to take products from unlicensed to licensed status. The division has a growing portfolio and pipeline of products that fit this unlicensed to licensed pathway, as well as complementary generic, generic plus or medical devices intended to meet unmet patient needs across a number of therapeutic areas.

Medication Adherence comprises two business units (Biodose® and Biodose Services®). This division provides products and services to enhance the likelihood of a patient adhering to a medication regime, patient-focused homecare services and services to pharmaceutical companies. It owns Biodose®, the only medication delivery system on the market that accommodates both liquid and solid doses. Biodose Connect™ takes patient safety and adherence to the next level by enabling remote monitoring of adherence to medication regimes. The division also operates a range of specialist patient-focused homecare services to the NHS, private clinics and pharmaceutical companies and provides the Group with exposure to the homecare and supported living sectors of the care pathway, complementing the focus of the remainder of the Group.

For further information, please visit www.quantumpharmaplc.com.